Predict your next investment

HEALTHCARE | Medical Devices & Equipment / Other Medical Devices
vessixvascular.com

See what CB Insights has to offer

Stage

Acquired | Acquired

Total Raised

$27.7M

Valuation

$0000 

About Vessix Vascular

Vessix Vascular, formerly known as Minnow Medical, is a privately-held pre-revenue stage company developing radiofrequency balloon catheter technology. The Company's initial product, the ZCath System, has a CE Mark for use in reducing plaque in peripheral leg arteries.In November 2012, Vessix Vascular was acquired by Boston Scientific. The valuation of Vessix Vascular was $425 million. Other terms of the deal were not released.

Vessix Vascular Headquarter Location

26052 Merit Circle Suite 106

Laguna Hills, California, 92653,

United States

949-916-1407

Latest Vessix Vascular News

Former Vessix Vascular CEO Appointed to BioVentrix Board

Oct 1, 2020

Former Vessix Vascular CEO Appointed to BioVentrix Board Former Vessix Vascular CEO Appointed to BioVentrix Board New board member has nearly 40 years of experience leading and guiding a variety of private and publicly traded life science companies. Business Wire10.01.20 BioVentrix Inc. , a privately held medical device company focused on treating congestive heart failure via Transcatheter Ventricular Restoration (TCVR), has appointed Raymond W. Cohen to the company’s board of directors. Cohen, an accredited public company director, has nearly 40 years of experience leading and guiding a variety of private and publicly traded life science companies as an executive and board member. Cohen currently serves as the CEO and member of the board of directors of Axonics Modulation Technologies Inc.   “Raymond Cohen is one of the most experienced leaders and directors in the industry when it comes to emerging medical technologies and has direct experience in the development of a device treatment for congestive heart failure. His successful track record of strategic exits for public and private companies, including Axonics’ successful IPO, will be invaluable as we envision an IPO of our own. We are delighted to welcome him to BioVentrix,” said BioVentrix CEO Ken Miller. Axonics executed a successful initial public offering in November 2018 and has since seen its market valuation increase five-fold to $1.7 billion. In its first quarter following U.S. Food and Drug Administration approval for its implantable neuromodulation device in the United States, Axonics generated the second-highest total of revenue in the history of the medical device industry. In addition to his role at Axonics, Cohen also serves as chairman of the board of NASDAQ-listed BioLife Solutions Inc., which in July raised $86 million in a follow-on public offering and has seen its market valuation rise to over $700 million. During the last few years, Cohen served as an independent director for NASDAQ-listed Spectrum Pharmaceuticals and also served on the board of two other companies that were recently acquired, including LifeWatch, a Swiss public company acquired by NASDAQ-listed Biotelemetry, and Syncroness, a private contract manufacturer acquired by ALTEN Group. From 2010–2012, Cohen served as CEO of Vessix Vascular, which was acquired by Boston Scientific Corp. at eight-times invested capital in late 2012. Earlier, he spent nearly a decade as chairman and CEO of NASDAQ-listed Cardiac Science Inc., which was ranked as the fourth-fastest growing company in the United States during his tenure. “I am enthusiastic about joining the BioVentrix board at an inflection point in the company’s history. The positive clinical results for the Revivent TC System one year post-implant recently published in a peer-reviewed journal are impressive. In addition, BioVentrix has achieved Breakthrough Designation by the U.S. FDA suggesting that BioVentrix, following the completion of its U.S. pivotal study, is poised to provide an important new minimally invasive treatment for ischemic heart failure patients who require intervention,” said Cohen. “The company’s technology is clearly unique, and I look forward to assisting management to bring this life-saving technology to the market to help heart failure patients.”   PR Newswire 10.01.20 PR Newswire 10.01.20 PR Newswire 10.01.20 GlobeNewswire 10.01.20 PR Newswire 10.01.20 GlobalData 10.01.20 Business Wire 10.01.20 PRNewswire 10.01.20 Business Wire 09.30.20 PR Newswire 09.30.20 Globe Newswire 09.30.20 PR Newswire 09.30.20 Business Wire 09.30.20 PR Newswire 09.30.20 GE Healthcare 09.30.20

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Vessix Vascular Patents

Vessix Vascular has filed 33 patents.

The 3 most popular patent topics include:

  • Vascular diseases
  • Angiology
  • Fuel cells
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/27/2016

7/27/2021

Vascular diseases, Implants (medicine), Drug delivery devices, Cardiology, Cardiac procedures

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

1/27/2016

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

7/27/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Vascular diseases, Implants (medicine), Drug delivery devices, Cardiology, Cardiac procedures

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.